anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pharmaceutical composition comprising emulsifying ointment and water substantially in the proportions A% and B% respectively of the total composition, where A + B is substantially 100% of the total composition and the ratio A:B is in the range 60:40 to 40:60 w/w. The composition may also include one or more substances in a proportion C% of the total composition, where C% is not more than 5% w/w. The C% may consist solely of preservative, e.g. phenoxyethanol. In a method of making the pharmaceutical composition, the emulsifying ointment and the water are heated, e.g. to substantially 60{C, stored together, and allowed to cool. The pharmaceutical composition may be applied to the skin, or used as a soap substitute.
FIELD: cosmetic industry. SUBSTANCE: invention relates to manufacturing shampoo with conditioning effect. Shampoo-conditioner comprises alkylethoxysulfate sodium, coconut oil fatty acid diethanolamide, heavy essential oil, anise oil, anhydrous lanolin, castor oil, vinylin (polyvinylbutyl ester), preserving agents, aromatic perfume and water. Components are taken in the definite quantitative ratio. Shampoo provides long-term cosmetic and curative effect and confers to hair the special luster and silky property and shows an antistatic effect also. EFFECT: valuable properties of shampoo. 2 cl, 2 ex
INTRODUCTION: Acute pancreatitis (AP) is a common disease, and several scores aim to assess its prognosis. Our study aims to automatically recognize mild AP from computed tomography (CT) images in patients with acute abdominal pain but uncertain diagnosis from clinical and serological data through Radiomic model based on formal methods (FMs).
METHODS: We retrospectively reviewed the CT scans acquired with Dual Source 256-slice CT scanner (Somatom Definition Flash; Siemens Healthineers, Erlangen, Germany) of 80 patients admitted to the radiology unit of Antonio Cardarelli hospital (Naples) with acute abdominal pain. Patients were divided into 2 groups: 40 underwent showed a healthy pancreatic gland, and 40 affected by four different grades (CTSI 0, 1, 2, 3) of mild pancreatitis at CT without clear clinical presentation or biochemical findings. Segmentation was manually performed. Radiologists identified 6 patients with a high expression of diseases (CTSI 3) to formulate a formal property (Rule) to detect AP in the testing set automatically. Once the rule was formulated, and Model Checker classified 70 patients into "healthy" or "unhealthy".
RESULTS: The model achieved: accuracy 81%, precision 78% and recall 81%. Combining FMs results with radiologists agreement, and applying the mode in clinical practice, the global accuracy would have been 100%.
CONCLUSIONS: Our model was reliable to automatically detect mild AP at primary diagnosis even in uncertain presentation and it will be tested prospectively in clinical practice.
While ITB therapy is commonly recommended for treatment of severe spasticity due to a variety of diseases, the location of optimal drug (baclofen) delivery has not been defined in a controlled study. Furthermore, the cost of pharmacological management in these patients is significant, and optimal location for drug delivery through an implantable drug pump may have significant impact on the cost burden of maintenance refills. It is the goal of this pilot study to determine whether there is a significant therapeutic advantage to place the ITB catheter within the cervical, thoracic or lumbar region of the spine. It is also a goal of this pilot study to determine whether the origin of spasticity influences the effect of Lioresal Intrathecal (baclofen injection) on ITB catheters located in the cervical, thoracic or lumbar regions of the spine. The investigators propose to study the impact of catheter location on the reduction in spasticity within a group of patients who are scheduled for ITB trial. In studying the impact of catheter location among patients with spinal versus cerebral origin of spasticity, the disease origin may also have a significant impact on baclofen dosing relative to the placement of the catheter.

In addition, the pharmacokinetic half-life and the variability of intrathecal baclofen is poorly understood as data is limited. In order to provide initial data regarding CSF baclofen washout, samples of spinal fluid obtained just prior to- and following IT baclofen administration will be obtained for delayed analysis. The results of these pharmacological analysis may refine the understanding of how quickly baclofen is distributed from a given catheter location, and whether it is affected by catheter location or disease origin. Since multiple catheter locations will be studied within a given patient, it also affords the opportunity to sample small amounts of CSF at key anatomical sites along the spinal axis as a secondary objective.
BACKGROUND: Surgery is the treatment of choice for patients with basal cell carcinoma (BCC). When surgery is not a choice, only radiotherapy is recommended for patients with high-risk facial BCC. Interferon could be an acceptable therapeutic option for these patients.
OBJECTIVE: To evaluate the long-term clinical response to interferon therapy in patients with high-risk facial BCC.
METHODS: Patients with high-risk facial BCC were treated with perilesional injections of alpha-2b+ gamma interferons. Those with incomplete clinical response were reevaluated, their residual tumors excised, and declared cured. Patients treated with interferon and those treated with interferon plus surgery were followed for five years. Time to recurrence and the emergence of a new facial BCC were estimated by Kaplan-Meier survival analysis. Adverse events were documented.
RESULTS: This study included 195 participants; 143 (73.3%) showed a complete response (95% CI 67.2‒80.1). Patients developed recurrence after a mean of 55 months (95% CI 53.8‒57.4). The estimated rate of recurrence was 12.3% (95% CI 7.4‒17.1). Patients developed a new BCC after a mean of 52.7 months (95% CI 50.4‒54.9). The estimated rate for development of a new BCC was 20.0% (95% CI 14.4‒25.9). Fifteen (7.7%) patients abandoned the study during follow-up. Adverse events were frequent but moderate or mild; fever and local pain were the most frequent.
STUDY LIMITATIONS: Observational cohort design without a control group for comparison.
CONCLUSIONS: Perilesional injections of alpha-2b+ gamma interferons in patients with facial high-risk BCC offer a satisfactory cure rate after five years of follow-up with an acceptable safety profile.
triCitrasol® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). Just prior to performing granulocytapheresis, aseptically add 30 mL of triCitrasol® to 500 mL of the 6% solution of Hydroxyethyl Starch (HES), e.g. Hespan ® 2-8. Agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. The resultant solution of triCitrasol® and 6% solution of HES contains the following concentration depending upon the volume used: 

The triCitrasol®/HES solution is stable for up to 24 hours at room temperature after mixing. 

Refer to the manufacturer's Operator's Manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure.
BACKGROUND: Opioid safety initiatives may secondarily impact opioid prescribing and pain outcomes for cancer care.
METHODS: We reviewed electronic health record data at a tertiary Veterans Affairs system (VA Palo Alto) for all patients from 2015 to 2021. We collected outpatient Schedule II opioid prescriptions data and calculated morphine milligram equivalents (MMEs) using Centers for Disease Control and Prevention conversion formulas. To determine the clinical impact of changes in opioid prescription, we used the highest level of pain reported by each patient on the 0-to-10 Numeric Rating Scale in each year, categorized into mild (0-3), moderate (4-6), and severe (7 and above).
RESULTS: Among 89 569 patients, 9073 had a cancer diagnosis. Cancer patients were almost twice as likely to have an opioid prescription compared with noncancer patients (69.0% vs 36.7%, respectively). The proportion of patients who received an opioid prescription decreased from 27.1% to 18.1% (trend P < .01) in cancer patients and from 17.0% to 10.2% in noncancer patients (trend P < .01). Cancer and noncancer patients had similar declines of MMEs per year between 2015 and 2019, but the decline was more rapid for cancer patients (1462.5 to 946.4, 35.3%) compared with noncancer patients (1315.6 to 927.7, 29.5%) from 2019 to 2021. During the study period, the proportion of noncancer patients who experienced severe pain was almost unchanged, whereas it increased among cancer patients, reaching a significantly higher rate than among noncancer patients in 2021 (31.9% vs 27.4%, P < .01).
CONCLUSIONS: Our findings suggest potential unintended consequences for cancer care because of efforts to manage opioid-related risks.
PURPOSE:To carry out fine granulation in water solvent and formation of capsule walls simultaneously by preparing fine capsules using self-dispersive resins which have dispersibility to disperse themselves to the degree to give average grain size smaller than a specific size under the function of water solvent. CONSTITUTION:Fine capsules consisting of a hydrophobic liquid and/or a solid substance (e.g. pigment) and a resin with which they are enclosed are manufactured. At that time, using self-dispersive resins (e.g. urethane resin) which has dispersibility to disperse themself to the degree to give <=0.1mum average grain size, fine capsules are prepared and fine granulation in water solvent and formation of capsule walls are carried out simultaneously. The super fine granular capsules prepared by the method can be formed easily within a short time without using auxiliary materials such as surfactants, etc., and have <=0.1mum average grain size. The capsules are especially applicable for recording materials such as pigments, inks, etc., and cosmetics and dyes for fibers.
In root research, hydroponic plant cultivation is commonly used and soil experiments are rare. We investigated the response of 12-day-old barley roots, cultivated in soil-filled rhizotrons, to different soil water potentials (SWP) comparing a modern cultivar (cv. Scarlett) with a wild accession ICB181243 from Pakistan. Water potentials were quantified in soils with different relative water contents. Root anatomy was studied using histochemistry and microscopy. Suberin and lignin amounts were quantified by analytical chemistry. Transcriptomic changes were observed by RNA-sequencing. Compared with control with decreasing SWP, total root length decreased, the onset of endodermal suberization occurred much closer towards the root tips, amounts of suberin and lignin increased, and corresponding biosynthesis genes were upregulated in response to decreasing SWP. We conclude that decreasing water potentials enhanced root suberization and lignification, like osmotic stress experiments in hydroponic cultivation. However, in soil endodermal cell suberization was initiated very close towards the root tip, and root length as well as suberin amounts were about twofold higher compared with hydroponic cultivation.
PURPOSE: Individuals with psychogenic non-epileptic seizures (PNES) can be stigmatized in healthcare settings. We aimed to compare intervention rate (IR), intervention time (IT), and adverse event (AE) rate between PNES and epileptic seizures (ES) in the epilepsy monitoring unit (EMU).
METHODS: We used a prospective database of consecutive admissions to our centre's EMU between August 2021 and September 2022. We excluded purely electric seizures and vague, minor spells with no EEG correlate. We therefore only included electroclinical seizures and PNES. We compared the IR, IT, and AE rate between PNES and ES, as diagnosed by an epileptologist during EEG monitoring. We performed the same comparisons between spells occurring in people admitted with a high vs low suspicion of PNES (HSP vs LSP). We also verified if ITs became longer with repeated PNES.
RESULTS: We analyzed 586 spells: 43 PNES vs 543 ES, or 133 HSP vs 453 LSP. Our univariate analyses showed that IR was higher for PNES than for ES (93 % vs 61 %, p <.001) but that IT and AE rate were similar across groups. This higher IR was only apparent outside weekday daytime hours, when EEG technologists were not present. HSP did not differ from LSP in terms of IR, IT, and AE rate. As PNES accumulated in individual patients, IT tended to be longer (Spearman's correlation = 0.42; p =.012).
SIGNIFICANCE: Our EMU staff did not intervene less or slower for PNES. Rather, IR was higher for PNES than for ES, but IT tended to be longer with repeat PNES.
The preparation of a cosmetic composition comprises circulating water through an enclosure containing product to extract the water and to collect the extracted solution in a container, and delivering the water without circulating in the enclosure to obtain a predefined volume of composition in the container. The quantity of injected water and delivered water are determined according to a color or coloring capacity of the obtained composition. Color related to a person is treated with the acquired composition in which the quantity of water is determined on the basis of the color. The preparation of a cosmetic composition comprises circulating water through an enclosure containing product to extract the water and to collect the extracted solution in a container, and delivering the water without circulating in the enclosure =80[deg]C to obtain a predefined volume of composition in the container. The quantity of injected water and delivered water are determined according to a color or col oring capacity of the obtained composition. Color related to a person is treated with the acquired composition in which the quantity of water is determined on the basis of the color. The quantity of delivered water is chosen to have a composition volume constant. The quantity of delivered water is determined by weighing the container and its contents, and by measuring the volume of the product in the container. The water is injected in the enclosure at higher than 80[deg]C and a pressure of >= 10 bars under vapor and liquid phase. The enclosure contains different products laid out on an extraction apparatus and/or refill. The enclosure optionally belongs to the same refill. The enclosures are partially defined by a first wall passed by an injector of the extraction apparatus, and by a second wall opened under the pressure effect of the injected water in the enclosure. Independent claims are included for: (1) an apparatus for the preparation of a cosmetic composition; and (2) a unit.
A method for preventing or treating overactive bladder includes administering a composition to a subject in need thereof. The composition includes extracts having a Corni Fructus extract, an Angelica gigantis Radix extract, a Lycii Fructus extract, a Cervi parvum cornu extract, a Ginseng Radix Rubra extract, and a Cassiae cortkex extract. The overactive bladder may be a complication of benign prostatic hyperplasia, and the composition may further include an alpha-1A adrenoceptor antagonist. The overactive bladder may be caused by secondary bladder degeneration occurring due to bladder outlet obstruction. The composition may be included in a pharmaceutical composition or a health functional food. The composition also exhibits an excellent effect on overactive bladder that is not relieved even when bladder outlet obstruction disappears by benign prostatic hyperplasia surgical treatment or administration of an alpha-blocker or the like.
The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification. The patient decision aid was designed to be utilised during and between the SDM-DC meetings. The patient decision aid is in paper format and consists of a set of tools: a decision map, an overview of uremic symptoms, an overview of options, and the Ottawa Personal Decision Guide. More specifically, the patient decision aid makes explicit the dialysis decision, describes options, benefits and harms using the best available evidence, and intends to help patients clarify their values by indicating the importance of the benefits and harms out of scale from (0) to (5). Four videos with personal stories were available to be shown and discussed at the meetings if the patient preferred to see the reason why another patient has chosen a specific option. Each video showed one option with a patient telling why he/she chose that option, and how he/she weighed the advantages and disadvantages.
BACKGROUND: In cases of wrist arthritis, proximal row carpectomy (PRC) has been widely utilized and shown favorable long-term outcomes. However, its applicability is limited in cases where arthritis extends to the lunate fossa or capitate. Recently, surgical approaches combining various methods of interposition arthroplasty have been introduced to overcome these drawbacks. The purpose of this study was to perform PRC and interposition arthroplasty with dorsal capsule and acellular dermal matrix(ADM),and analyze the clinical outcomes of these procedures.
METHODS: Fourteen cases who underwent PRC and interposition arthroplasty using both dorsal capsular flap and ADM were retrospectively recruited. The researchers assessed the patients' Visual Analog Scale (VAS) pain score, Disabilities of the Arm, Shoulder and Hand (DASH) scores, range of motion (ROM), retear, and radiocarpal distance (RCD).
RESULTS: One year post-surgery, both the VAS pain scores, DASH scores, and ROM showed statistically significant improvement compared to before the surgery. Upon reviewing the radiological results, the postoperative mean RCD was 4.8 ± 0.8 mm and one year follow up mean RCD was 3.6 ± 0.5 mm at one year post-surgery. Moreover, in the one year follow-up, there was no observed failure of the allodermis graft in any of the cases.
CONCLUSION: The PRC and interposition arthroplasty with ADM demonstrated significantly improved clinical outcomes after surgery, showing a maintain of RCD without graft failure effectively.
Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
Tamoxifen can cause fetal harm when administered to a pregnant woman. There are postmarketing reports of vaginal bleeding, spontaneous abortions, birth defects, and fetal deaths in pregnant women taking tamoxifen. In a primate model, administration of tamoxifen at doses 2 times the maximum recommended human dose resulted in spontaneous abortion. In rat and rabbit studies, doses of tamoxifen less than or equal to human doses resulted in increased embryotoxicity, abortions, and altered learning behaviors in the offspring. Additionally, rodent models showed reproductive tract changes often associated with diethylstilbestrol (DES) in offspring of both sexes.

Advise pregnant women of the potential risks to a fetus, including the potential long-term risk of a DES-like syndrome. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with tamoxifen and for 2 months following the last dose [see Use in Specific Populations (8.1, 8.3)].
Due to the low systemic absorption of topically-applied diclofenac sodium gel, 3%, overdosage is unlikely. There have been no reports of ingestion of diclofenac sodium gel, 3%. In the event of oral ingestion, resulting in significant systemic side effects, it is recommended that the stomach be emptied by vomiting or lavage. Forced diuresis may theoretically be beneficial because the drug is excreted in the urine. The effect of dialysis or hemoperfusion in the elimination of diclofenac (99% protein-bound) remains unproven. In addition to supportive measures, the use of oral activated charcoal may help to reduce the absorption of diclofenac. Supportive and symptomatic treatment should be given for complications such as renal failure, convulsions, gastrointestinal irritation and respiratory depression.
Cerium oxide nanoparticles (CNPs) have been proven to exhibit antioxidant properties attributed to its surface oxidation states (Ce4+ to Ce3+ and vice versa) mediated at the oxygen vacancies on the surface of CNPs. Different anions in precursor cerium salts were used to prepare CNPs resulting in disclosed CNPs with varying physicochemical properties such as dispersion stability, hydrodynamic size, and the signature surface chemistry. The antioxidant catalytic activity and oxidation potentials of different CNPs have been significantly altered with the change of anions in the precursor salts. For one, CNPs prepared using precursor salts containing NO3− and Cl− ions exhibited increased antioxidant activity than previously thought possible. The change in oxidation potentials of CNPs with the change in concentration of the nitrate and chloride ions indicates the disclosed CNP's have different surface chemistry and antioxidant properties. These compositions and methods of their synthesis are disclosed.
This is a prospective cross-sectional interventional design. 73 asthmatic patients who applied to Mersin University Faculty of Medicine Hospital Chest Diseases Clinic between 01.10.2019-01.04.2020 will be taken. 35 healthy volunteers who were admitted to our clinic within the same date range will be taken as control group. Impulse oscillometric pulmonary function tests will be performed to all participants. Thorax computed tomography will be performed to evaluate small airway dysfunction. To evaluate the degree of disease inflammation and phenotype in asthma patients, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. The blood eosinophil level will be studied to determine the asthma phenotype.Asthma control test (ACT) will be applied to measure symptom control in patients with asthma. Asthma quality of life scale (AQLQ) will be applied to determine the quality of life in asthmatic patients. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma. The effect of small airway dysfunction on asthma group, on the disease severity and control degree, disease phenotypes and quality of life, and the effect on the risk of exacerbation will be analyzed.